Crispr Screen Analyzerv0.1.0

A biotech company runs a genome-wide CRISPR viability screen in cancer cell lines to identify genes essential for survival. Using the analyzer, they perform quality control, calculate fold changes, and apply RRA to pinpoint candidate drug targets. The output hit list is then used for downstream pathway enrichment and validation experiments.

An academic lab treats cancer cells with a targeted therapy and screens for genes whose knockout confers resistance. The analyzer processes treatment vs control samples to detect enriched sgRNAs, revealing novel resistance mechanisms. These hits guide further mechanistic studies and potential combination therapy strategies.

A precision medicine company screens for genes that become essential only in the presence of a specific drug or genetic background. The analyst compares screen data across conditions to identify synthetic lethal interactions. The resulting gene list provides candidates for drug combination development.

A researcher needs to validate screen quality metrics before submitting a manuscript. They use the QC module to compute Gini index, read depth, and dropout rates across replicates. The output confirms high-quality data, ensuring robust statistical analysis and reliable hit identification.

Offer CRISPR screen analysis as a paid service to biotech and pharma clients who need expert data processing. Each analysis project is billed, with additional charges for advanced customization or prioritized turnaround.

Provide the analyzer as a cloud-based platform with tiered subscription plans. Users access automated analysis pipelines and pay monthly or annually, with premium tiers offering increased compute resources or priority support.

Offer workshops and consulting services to help research institutions integrate the analyzer into their workflows. Revenue comes from training sessions, custom script development, and ongoing support contracts.